ReviewCurrent opinion in virology2014
The development of new therapies for human herpesvirus 6.
Review in Current opinion in virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy.Transplantation and cellular therapy · 2025Guideline
- Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Analysis Of Salivary Herpesviruses Reveals Associations Between HHV-6 And Long COVID Severity.medRxiv : the preprint server for health sciences · 2026Article
- Review
- Article
- Comparison of Droplet Digital PCR and Metagenomic Next-Generation Sequencing Methods for the Detection of Human Herpesvirus 6B Infection Using Cell-Free DNA from Patients Receiving CAR-T and Hematopoietic Stem Cell Transplantation.Infection and drug resistance · 2022Article
- Herpesvirus-Associated Encephalitis: an Update.Current tropical medicine reports · 2022Review
- Natural Products and Their Derivatives against Human Herpesvirus Infection.Molecules (Basel, Switzerland) · 2021Review
- The Spectrum of Neurological Manifestations of Human Herpesvirus 6 Infection in Children.Cureus · 2021Article
- Persistent viremia in an immunocompetent patient with inherited chromosomally integrated HHV-6B.Access microbiology · 2021Article
- Herpes simplex virus 1 rhombencephalitis in a patient with chromosomally integrated human herpesvirus-6A.IDCases · 2020Article
- Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications.Bone marrow transplantation · 2020Article
- Review
- Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6B.Journal of virology · 2019Article
- Antiviral Therapies for Herpesviruses: Current Agents and New Directions.Clinical therapeutics · 2018Review
- The Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies.Viruses · 2018Review
- Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6.Frontiers in immunology · 2018Review
- Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals.Journal of neurovirology · 2017Review
- Human Herpesvirus 6 Infection Presenting as an Acute Febrile Illness Associated with Thrombocytopenia and Leukopenia.Case reports in pediatrics · 2016Article
- The Diagnosis and Treatment of Autoimmune Encephalitis.Journal of clinical neurology (Seoul, Korea) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Human herpesvirus 6 (HHV-6) infections are typically mild and in rare cases can result in encephalitis. A common theme among all the herpesviruses, however, is the reactivation upon immune suppression. HHV-6 commonly reactivates in transplant recipients. No therapies are approved currently for the treatment of these infections, although small studies and individual case reports have reported intermittent success with drugs such as cidofovir, ganciclovir, and foscarnet. In addition to the current experimental therapies, many other compounds have been reported to inhibit HHV-6 in cell culture with varying degrees of efficacy. Recent advances in the development of new small molecule inhibitors of HHV-6 will be reviewed with regard to their efficacy and spectrum of antiviral activity. The potential for new therapies for HHV-6 infections will also be discussed, and they will likely arise from efforts to develop broad spectrum antiviral therapies for DNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.